Ideally, autologous iPS cells will be used for cell therapy transplantations. However, to do so necessitates the patient's own cells, such as blood cells, be reprogrammed to iPS cells and differentiated into the cell type required for transplantation. Each step involves careful cell manipulation, from reprogramming to differentiation, and requires strict quality control. To make iPS cell therapies accessible to a large population, the CiRA Foundation is developing technologies necessary to manufacture one's own iPS cells at low costs autologous.

Manufacturing iPS cells at a cost of 1 million yen by 2025

Currently, iPS cell manufacturing takes several months and costs tens of millions of yen. Reducing the time and cost must be done without compromising the safety or efficacy of the iPS cells. We therefore seek the collaboration of companies and scientists to achieve this goal.

• Contact Us